BioPharm International August 2018

August 2018 | Volume 31, Issue 8
BioPharm International August 2018 Issue
Cover Story
The quality of the cell lines used to manufacture biopharmaceuticals are crucial for the production of high-quality, stable biopharmaceuticals.
Features
Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.
More complex biologic samples must be evaluated to ever higher levels of specificity and sensitivity.
Materials in contact with a drug must be fully characterized to ensure they do not negatively affect the safety and efficacy of the product.
The changing regulatory and manufacturing environment is ushering in a new approach to drug development.
Regulatory Beat
The agency is asking firms to discuss internal quality metrics efforts as part of the approval process for new medical products.
From the Editor
Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.
Ask the Expert
The type of product, the packaging materials being used, and the process and materials used to manufacture the product will determine when E&L data should be submitted to regulators, says Susan J. Schniepp, executive vice-president, Post-approval Pharmaceuticals and distinguished fellow at Regulatory Compliance Associates.
native1_300x100
lorem ipsum